权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

TOWARDS ELECTRICALLY ENRICHED MESENCHYMAL STEM CELLS FOR TREATMENT OF EARLY INFLAMMATORY OSTEOARTHRITIS

利用电富集间充质干细胞治疗早期炎症性骨关节炎

基本信息

批准号：
9809453
负责人：
Mariah S Hahn
金额：
$ 8.1万
依托单位：
RENSSELAER POLYTECHNIC INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-07-15 至 2021-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9809453
关键词：
3-Dimensional Address Adult Biological Models Biomedical Engineering Biometry Cartilage Cell Therapy Cell membrane Cells Chondrocytes Clinical Data Degenerative Disorder Degenerative polyarthritis Disease Disease Marker Disease model Early treatment Evaluation Exhibits Fluorescence-Activated Cell Sorting Future Gene Proteins Genetic Goals Health Human In Vitro Inflammation Inflammatory Injections Joints Lead Literature Membrane Potentials Mesenchymal Stem Cells Metabolism Methylprednisolone Modeling Natural regeneration Outcome Pathogenesis Patients Population Heterogeneity Property Protocols documentation Risk Sorting - Cell Movement Stem cells Technology Therapeutic Tissues Treatment Efficacy Work base combat cytokine design disability disease phenotype electrical potential electrical property embryonic stem cell immunoregulation improved in vitro Model in vivo inflammatory milieu macrophage mitochondrial membrane novel prevent proteostasis regenerative senescence stem cell differentiation stem cell therapy stemness

项目摘要

PROJECT ABSTRACT Osteoarthritis (OA) is a disabling, degenerative disease that involves every tissue in the joint. The inflammatory environment surrounding these tissues is believed to fundamentally underlie OA pathogenesis and may therefore hold a key to treatment. One prominent end result of this dysregulated inflammatory state is long- term, progressive cartilage tissue degradation. Effective disease modifying treatments that can intervene in this degradative cascade are not currently available. Human mesenchymal stem cell (hMSC) injections are emerging as a potential disease modifying treatment for OA due to their multi-faceted immunomodulatory properties. However, hMSC injections suffer from substantial variability in efficacy which can be attributed in part to the inherent complexity of using cells which contain significant population heterogeneity/cell states with varying levels of senescence. We therefore propose: 1) to develop a therapy based on hMSCs enriched for electrical properties associated with superior stemness and immunomodulatory/regenerative capacity and 2) to assess the therapeutic potential of these electrically enriched hMSCs using an in vitro model of early inflammatory OA. We envision that electrical enrichment can be implemented as a novel component of hMSC therapy for combating inflammation and promoting regeneration in OA.

项目摘要